The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

Please provide your email address to receive an email when new articles are posted on . The Digihaler records data on inhaler usage and inhalation quality, which is then shared with the patient ...

Please provide your email address to receive an email when new articles are posted on . Mean Asthma Control Questionnaire-6 scores fell from 2.6 at baseline to 1.4 at week 52. 47.3% had partially or ...

Asthma guidelines focus on day-to-day control of symptoms. However, asthma attacks remain common. They continue to cause mortality and considerable morbidity, and are a major financial burden to the ...

Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and potential for precision prescribing remain unclear. Biomarker-guided approaches ...

A new research study, published in JAMA Cardiology, aimed to further confirm a previous correlation between asthma and atrial fibrillation (AF) and to determine if the degree of asthma control ...

—These data suggest that small airway disease, as measured by physiological testing, is correlated with an increased risk of asthma symptoms and exacerbations. Reviewed by Ware Kuschner, MD, Professor ...